Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)
Clinical trial NCT05037188 · TERMINATED
Trial details
- NCT number
- NCT05037188
- Sponsor
- Biocad
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-10
- Primary completion
- 2022-04-18
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.